T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$2.57B |
| 2 |
GE Aerospace
GE
|
+$1.8B |
| 3 |
UnitedHealth
UNH
|
+$1.63B |
| 4 |
Marriott International
MAR
|
+$1.62B |
| 5 |
Apple
AAPL
|
+$1.3B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.87B |
| 2 |
JPMorgan Chase
JPM
|
+$1.64B |
| 3 |
Nike
NKE
|
+$1.59B |
| 4 |
Becton Dickinson
BDX
|
+$1.46B |
| 5 |
Alibaba
BABA
|
+$1.32B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.97% |
| 2 | Healthcare | 18.52% |
| 3 | Consumer Discretionary | 13.26% |
| 4 | Financials | 12.08% |
| 5 | Communication Services | 10.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2051
Amkor Technology
AMKR
$14.4B
| $426K | ﹤0.01% |
54,665
-15,666
| -22% | -$170K |
|
2052
Hyster-Yale Materials Handling
HY
$618M
| $425K | ﹤0.01% |
10,598
+60
| +0.6% | +$3.02K |
|
|
ZYNE
2053
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $425K | ﹤0.01% |
111,048
+41,300
| +59% | +$192K |
|
|
CALA
2054
DELISTED
Calithera Biosciences, Inc
CALA
| $424K | ﹤0.01% |
4,770
+121
| +3% | +$14.4K |
|
|
HTGM
2055
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
| $423K | ﹤0.01% |
7,226
-535
| -7% | -$52.4K |
|
2056
Kinsale Capital Group
KNSL
$8.55B
| $421K | ﹤0.01% |
+4,027
| New | +$454K |
|
|
AHPI
2057
DELISTED
Allied Healthcare Products
AHPI
| $420K | ﹤0.01% |
+24,000
| New | +$187K |
|
2058
Crinetics Pharmaceuticals
CRNX
$8.96B
| $418K | ﹤0.01% |
28,408
-7,700
| -21% | -$158K |
|
2059
Pure Cycle
PCYO
$273M
| $418K | ﹤0.01% |
37,483
+100
| +0.3% | +$1.21K |
|
|
RESI
2060
DELISTED
Front Yard Residential Corporation Common Stock
RESI
| $418K | ﹤0.01% |
34,960
+300
| +0.9% | +$3.51K |
|
2061
First Commonwealth Financial
FCF
$2.18B
| $417K | ﹤0.01% |
45,630
+5,749
| +14% | +$71.2K |
|
2062
Pacific Biosciences
PACB
$364M
| $417K | ﹤0.01% |
136,219
+41,441
| +44% | +$170K |
|
2063
Sterling Infrastructure
STRL
$16.9B
| $417K | ﹤0.01% |
43,895
+7,050
| +19% | +$89.8K |
|
2064
United Natural Foods
UNFI
$2.9B
| $417K | ﹤0.01% |
45,430
-70,408
| -61% | -$558K |
|
2065
First Business Financial Services
FBIZ
$600M
| $416K | ﹤0.01% |
26,810
-1,012
| -4% | -$23.1K |
|
2066
Herc Holdings
HRI
$5.65B
| $416K | ﹤0.01% |
20,312
-1,999
| -9% | -$72.9K |
|
|
OMN
2067
DELISTED
OMNOVA Solutions Inc.
OMN
| $416K | ﹤0.01% |
41,030
+1,365
| +3% | +$13.6K |
|
|
TPC
2068
Tutor Perini Cor
TPC
$5.04B
| $413K | ﹤0.01% |
61,483
+25,169
| +69% | +$269K |
|
2069
Interparfums
IPAR
$3.74B
| $410K | ﹤0.01% |
8,839
-1,373
| -13% | -$85.8K |
|
2070
Omega Flex
OFLX
$278M
| $410K | ﹤0.01% |
4,860
-2,813
| -37% | -$255K |
|
|
KBAL
2071
DELISTED
Kimball International
KBAL
| $410K | ﹤0.01% |
34,441
+5,700
| +20% | +$94.8K |
|
2072
Dana Inc
DAN
$3.27B
| $409K | ﹤0.01% |
52,399
+8,782
| +20% | +$121K |
|
|
FFIC
2073
DELISTED
Flushing Financial
FFIC
| $407K | ﹤0.01% |
30,438
+6,057
| +25% | +$111K |
|
2074
1-800-Flowers.com
FLWS
$265M
| $406K | ﹤0.01% |
30,672
+138
| +0.5% | +$2.13K |
|
|
EGOV
2075
DELISTED
NIC Inc
EGOV
| $406K | ﹤0.01% |
+17,673
| New | +$361K |
|
Similar funds
T. Rowe Price Associates's Q1 2020 Portfolio in Review
As of Q1 2020, T. Rowe Price Associates held 2,612 positions worth $632B, down 18% from $771B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2020 filing shows 87 new, 1,525 increased, 823 reduced and 103 closed positions. Its largest new stake was Philips: 33,363,001 shares worth $1.07B. The largest sale was Boeing, an estimated $2.87B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2020 buy was Philips: 33,363,001 shares worth $1.07B.
- T. Rowe Price Associates added most to Humana in Q1 2020, an estimated $2.57B increase.
- T. Rowe Price Associates's biggest Q1 2020 reduction was Boeing, cutting an estimated $2.87B.
- T. Rowe Price Associates fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $846M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $632B portfolio in Q1 2020.
- T. Rowe Price Associates opened 87 new positions and closed 103 in Q1 2020.
- T. Rowe Price Associates's portfolio value fell 18% quarter-over-quarter to $632B.
Based on T. Rowe Price Associates's 13F filing for Q1 2020, filed 15 May 2020.